Leveraging technological and R&D strength, Artivila has established a global pipeline portfolio of small-molecule drugs with high innovation and commercial potential. Artivila is currently focused on Autoimmune diseases, Neurodegenerative diseases and Cancers, where there is a huge unmet need for treatment.

• Therapeutic Area
  Program
  Hit/Lead Identification
  Lead Optimization
  Pre-clinical
  IND
  Commercial Rights
• Autoimmune Disease
  Ignite (ARD-885)

  Global

  Refresh

  Global

  Jump

  Global
• Neurodegenerative Disease
  Sunrise

  Global

  Lift

  Global
• Cancer
  MM01 (ARD-198)

  Global

  Climb

  Global

  Leap

  Global

Swipe right to see more